Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 251

1.

A trial like ALIC<sup>4</sup>E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness?

Butler CC, Coenen S, Saville BR, Cook J, van der Velden A, Homes J, de Jong M, Little P, Goossens H, Beutels P, Ieven M, Francis N, Moons P, Bongard E, Verheij T.

ERJ Open Res. 2018 May 8;4(2). pii: 00046-2018. doi: 10.1183/23120541.00046-2018. eCollection 2018 Apr.

2.

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.

de Boer PT, Kelso JK, Halder N, Nguyen TP, Moyes J, Cohen C, Barr IG, Postma MJ, Milne GJ.

Vaccine. 2018 Feb 8;36(7):997-1007. doi: 10.1016/j.vaccine.2017.12.073. Epub 2018 Jan 17.

3.

Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.

Wateska AR, Nowalk MP, Zimmerman RK, Smith KJ, Lin CJ.

BMC Infect Dis. 2018 Jan 25;18(1):52. doi: 10.1186/s12879-018-2967-2.

4.

The Korean Influenza National Immunization Program: History and Present Status.

Yun JW, Noh JY, Song JY, Chun C, Kim Y, Cheong HJ.

Infect Chemother. 2017 Dec;49(4):247-254. doi: 10.3947/ic.2017.49.4.247. Review.

5.

Influenza-associated mortality in Yancheng, China, 2011-15.

Zhang H, Xiong Q, Wu P, Chen Y, Leung NHL, Cowling BJ.

Influenza Other Respir Viruses. 2018 Jan;12(1):98-103. doi: 10.1111/irv.12487. Epub 2017 Nov 28.

6.

fluEvidenceSynthesis: An R package for evidence synthesis based analysis of epidemiological outbreaks.

van Leeuwen E, Klepac P, Thorrington D, Pebody R, Baguelin M.

PLoS Comput Biol. 2017 Nov 20;13(11):e1005838. doi: 10.1371/journal.pcbi.1005838. eCollection 2017 Nov.

7.

Amplified visual immunosensor integrated with nanozyme for ultrasensitive detection of avian influenza virus.

Ahmed SR, Corredor JC, Nagy É, Neethirajan S.

Nanotheranostics. 2017 Jul 8;1(3):338-345. doi: 10.7150/ntno.20758. eCollection 2017.

8.

Both hemispheric influenza vaccine recommendations would have missed near half of the circulating viruses in Madagascar.

Guillebaud J, Héraud JM, Razanajatovo NH, Livinski AA, Alonso WJ.

Influenza Other Respir Viruses. 2017 Nov;11(6):473-478. doi: 10.1111/irv.12517.

9.

The appropriateness of the use of influenza vaccines: Recommendations from the latest seasons in Italy.

Bonanni P, Boccalini S, Zanobini P, Dakka N, Lorini C, Santomauro F, Bechini A.

Hum Vaccin Immunother. 2018 Mar 4;14(3):699-705. doi: 10.1080/21645515.2017.1388480. Epub 2017 Dec 1.

10.

The impact of influenza on the health related quality of life in China: an EQ-5D survey.

Yang J, Jit M, Zheng Y, Feng L, Liu X, Wu JT, Yu H.

BMC Infect Dis. 2017 Oct 16;17(1):686. doi: 10.1186/s12879-017-2801-2.

11.

Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health.

Hirve S, Kroeger A, Matlashewski G, Mondal D, Banjara MR, Das P, Be-Nazir A, Arana B, Olliaro P.

PLoS Negl Trop Dis. 2017 Oct 12;11(10):e0005889. doi: 10.1371/journal.pntd.0005889. eCollection 2017 Oct. Review.

12.

Variation in loss of immunity shapes influenza epidemics and the impact of vaccination.

Woolthuis RG, Wallinga J, van Boven M.

BMC Infect Dis. 2017 Sep 19;17(1):632. doi: 10.1186/s12879-017-2716-y.

13.

Prevention and assessment of infectious diseases among children and adult migrants arriving to the European Union/European Economic Association: a protocol for a suite of systematic reviews for public health and health systems.

Pottie K, Mayhew AD, Morton RL, Greenaway C, Akl EA, Rahman P, Zenner D, Pareek M, Tugwell P, Welch V, Meerpohl J, Alonso-Coello P, Hui C, Biggs BA, Requena-Méndez A, Agbata E, Noori T, Schünemann HJ.

BMJ Open. 2017 Sep 11;7(9):e014608. doi: 10.1136/bmjopen-2016-014608. Review.

14.

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.

Thorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M.

BMC Med. 2017 Sep 8;15(1):166. doi: 10.1186/s12916-017-0932-3.

15.

Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age.

Kittikraisak W, Suntarattiwong P, Ditsungnoen D, Pallas SE, Abimbola TO, Klungthong C, Fernandez S, Srisarang S, Chotpitayasunondh T, Dawood FS, Olsen SJ, Lindblade KA.

PLoS One. 2017 Aug 24;12(8):e0183391. doi: 10.1371/journal.pone.0183391. eCollection 2017.

16.

Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England.

Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M.

Lancet Public Health. 2017 Jul 31;2(8):e367-e374. doi: 10.1016/S2468-2667(17)30103-2. eCollection 2017 Aug.

17.

Pricing Externalities to Balance Public Risks and Benefits of Research.

Farquhar S, Cotton-Barratt O, Snyder-Beattie A.

Health Secur. 2017 Jul/Aug;15(4):401-408. doi: 10.1089/hs.2016.0118. Epub 2017 Aug 2.

18.

Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting.

You JHS, Tam LP, Lee NLS.

PLoS One. 2017 Jul 27;12(7):e0182091. doi: 10.1371/journal.pone.0182091. eCollection 2017.

19.

Cost-effectiveness analysis of N95 respirators and medical masks to protect healthcare workers in China from respiratory infections.

Mukerji S, MacIntyre CR, Seale H, Wang Q, Yang P, Wang X, Newall AT.

BMC Infect Dis. 2017 Jul 3;17(1):464. doi: 10.1186/s12879-017-2564-9.

20.

Protecting an island nation from extreme pandemic threats: Proof-of-concept around border closure as an intervention.

Boyd M, Baker MG, Mansoor OD, Kvizhinadze G, Wilson N.

PLoS One. 2017 Jun 16;12(6):e0178732. doi: 10.1371/journal.pone.0178732. eCollection 2017.

Supplemental Content

Loading ...
Support Center